Curia to Expand U.S. Commercial Manufacturing Capability
19.8.2021 16:00:00 EEST | Business Wire | Press release
Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced plans to expand its commercial manufacturing capacity at its Rensselaer, New York facility. The increased capability to flexibly manufacture complex Active Pharmaceutical Ingredients (APIs) will further strengthen Curia’s ability to partner with customers, meeting small-scale to large-volume requirements with reliable delivery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005107/en/
Curia’s Rensselaer, New York facility. (Photo: Business Wire)
Curia is investing more than $35 million in these state-of-the-art expanded manufacturing and product-handling solutions for complex small molecules. The expansion will include new vessel capacities that more than double the site’s batch-size scaling and product output. It will allow for the introduction of a variety of new products and enable Curia to meet growing demand for high potency API manufacturing.
The expansion will generate new technical jobs in Rensselaer. Consistent with Curia’s commitment to environmental stewardship, the expansion plans include optimization of energy usage and enhanced environmental standards as integral elements.
“Our Rensselaer team’s history of excellence in delivering U.S.-based complex manufacturing solutions that enable our customers to provide vital treatments to patients is resulting in increasing demand,” said Curia Chairman and CEO John Ratliff. “Some of the life-saving products produced at Rensselaer are highly complex, including critical oncology therapeutics and novel treatments addressing unmet medical needs. The engineering and technology advances we have designed for the site will enhance our flexibility, efficiency and scale, allowing us to meet our customers’ current and future complex manufacturing needs.”
Curia’s Rensselaer facility has provided high-quality APIs to global pharmaceutical companies for more than 100 years. The site currently produces APIs to meet the development and commercial needs of more than 50 products. It was the first facility in the industry to be designated “Industry Leader” as part of its re-certification under the independent SafeBridge® program for “Potent Compound Safety Certification” in 2020.
The expansion is expected to be completed within 18 months, adding to Curia’s existing breadth of API manufacturing facilities in the U.S., France, Spain, Italy and India, each supporting flexible manufacturing solutions for orders ranging from grams to metric tons, to provide seamless support to customers along the R&D and manufacturing continuum.
About Curia
Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,400 employees at 23 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005107/en/
Contact information
Corporate Contact:
Sue Zaranek
Curia
+1 518 512 2111
corporatecommunications@CuriaGlobal.com
Media Communications:
Debra Harrsch
Brandwidth Solutions LLC
+1 215 997 8575
dharrsch@bwsmarketing.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Torq Acquires Jit to Unleash the First Enterprise AI SOC Context Graph—and Rewrite the Future of SecOps19.5.2026 16:00:00 EEST | Press release
Torq, the established agentic security operations leader, today announced the acquisition of Jit, the Boston-based AI Context Graph cybersecurity pioneer. This move marks a dramatic leap forward for the Torq AI SOC Platform by ensuring agentic investigations are precisely informed via organization-specific contextual data. This shift redefines agentic reasoning, moving beyond static facts such as users, devices and their relationships, to prioritize live, dynamic contextual data overlaid on top, including business drivers, and the real-time state of the enterprise. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519044833/en/ Instead of acting on fragmented data or having investigations triggered by a single alert, Torq AI operates with a unified, continuously-updated, contextual inference, enabling decisions that are not only explainable, but inherently grounded in a single and up-to-date source of truth. This reflects no
Cohere Acquires Reliant AI to Expand Sovereign Enterprise AI for the Global Biopharma and Healthcare Sectors19.5.2026 16:00:00 EEST | Press release
Cohere, the world’s leading sovereign AI company, announced today the acquisition of Reliant AI, a leading biopharma AI company with operations in Montreal and Berlin. This acquisition brings Reliant AI’s world-class research team, proprietary biomedical datasets, and domain-optimized technology into Cohere’s enterprise-grade sovereign AI platform. This significantly expands Cohere’s footprint in the global healthcare and life sciences sectors–where security, data privacy, and regulatory compliance are paramount—and builds on Cohere’s existing partnerships across administrative, clinical, and revenue cycle workflows. The acquisition strengthens Cohere’s position as global sovereign AI leader, building on its established presence in Canada and Germany and growing momentum across Europe. Together, Cohere and Reliant AI will equip healthcare and life sciences enterprises with a powerful combination of cutting-edge AI technology, secure deployment options for highly regulated environments,
NordicTrack’s Most Ambitious Pilates Machine Yet: Introducing the Ultra 1 Reformer19.5.2026 16:00:00 EEST | Press release
NordicTrack is bringing studio-grade Pilates directly into the home with the Ultra 1 Reformer, available to order May 19 at NordicTrack.com for $US4,999. Blending luxury craftsmanship with smart technology, this consumer-focused model offers a studio‐quality Pilates experience that fits effortlessly into modern living. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519139005/en/ NordicTrack Ultra 1 Reformer Pilates has become a cornerstone of modern wellness, recognized for building core strength, improving flexibility, and fostering a deep mind-body connection. Recognizing this growing demand, NordicTrack’s new reformer pairs elegant design with an integrated HD touchscreen and seamless access to expert‐led classes through the iFIT platform. “The Ultra 1 Reformer is the first Pilates machine that earns its place in your home. Real equipment, personalized expert instruction, and the results we are all seeking,” says Kevin
CreditNature and Stabiliti Partner to Embed Nature Finance into Everyday Economic Activity19.5.2026 15:48:00 EEST | Press release
CreditNature, a pioneering Nature Fintech company, today announces a strategic partnership with Stabiliti, a nature-focused technology company building the infrastructure to embed environmental contributions into everyday economic activity. Together, the partnership will enable businesses to embed measurable nature impact into everyday operations, bridging the gap between commercial activity and ecosystem restoration at unprecedented scale. The collaboration addresses a critical challenge in nature finance: how to mobilise investment at the scale required to meet global biodiversity targets. By integrating CreditNature's scientifically accredited NARIA framework with Stabiliti's embedded infrastructure, businesses can now channel micro-contributions from routine commercial and financial activity directly into verified nature restoration projects. This partnership represents a significant step in CreditNature's mission to scale investment into ecosystem recovery, making it possible for
Gustave Roussy and One Biosciences Partner to Bring Single Cell to Clinical Practice for Precision Oncology19.5.2026 14:02:00 EEST | Press release
Gustave Roussy partners with One Biosciences, a techbio company that harnesses single cell technology and AI to develop advanced precision diagnostics. The collaboration aims to further demonstrate the feasibility and impact of integrating single nuclei transcriptomic analysis into the patient care pathway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519540709/en/ Gustave Roussy, Europe’s leading cancer center, is teaming up with One Biosciences to harness the cutting-edge potential of OneMapTM, the single-cell and AI-powered solution helping to enhance precision oncology solutions. By analyzing anonymized frozen samples across four cancer indications, One Biosciences will deploy OneMapTM to generate ultra-high-resolution single-cell data, unlocking the hidden functional diversity of each tumor with unparalleled precision. Prof. Sophie Postel-Vinay, oncologist at Gustave Roussy, team leader in Inserm unit U981 at Gusta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom